Compare
Longevity protocols, side by side.
Every protocol profiled on variis, on the same table. Evidence level, categories, and sources, all graded and dated.
2 of 2 protocols. Scroll horizontally on narrow screens.
| Attribute | GLP-1 receptor agonistsLatest coverageGLP-1s and healthspan: a 2026 reader’s primer | Rapamycin / mTOR inhibition |
|---|---|---|
| Evidence | Clinical | Preclinical |
| Also known as | semaglutide, tirzepatide, orforglipron | sirolimus |
| Categories | – | – |
| Evidence summary | The most consumer-discussed longevity-adjacent class; the editorial frame is "are GLP-1s the first true healthspan drugs?" | The most-studied geroprotective; selective mTORC1 inhibitors in development. |
| Offered by | – | – |
| Sources | – | – |
Not medical advice.